AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26902366 — intervention group
Group type: EXPERIMENTAL
Intervention: GSD-GYN-C plus usual care (UC)
Number of subjects: 165
Study 26902366 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) alone
Number of subjects: 165
Study 25242076 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-layer compression hosiery (HH)
Number of subjects: 457
Study 25242076 — intervention group
Group type: COMPARATOR
Intervention: Four-layer bandage (4LB)
Number of subjects: 457
Study 25242076 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-layer bandage (2LB)
Number of subjects: 457
Study 22807523 — intervention group
Group type: EXPERIMENTAL
Intervention: RBV induction (2000 mg/d) plus erythropoietin β (450 IU/kg/wk)
Number of subjects: 357
Study 22807523 — intervention group
Group type: COMPARATOR
Intervention: RBV standard dosing (1000 or 1200 mg/d)
Number of subjects: 357
Study 22807523 — intervention group
Group type: EXPERIMENTAL
Intervention: RBV induction plus erythropoietin
Number of subjects: 357
Study 22807523 — intervention group
Group type: COMPARATOR
Intervention: RBV standard dosing
Number of subjects: 357
Study 22807523 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 357
Study 21162963 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment Maneuver (RM) group
Number of subjects: 110
Study 21162963 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study 17933159 — intervention group
Group type: COMPARATOR
Intervention: EMLA cream
Number of subjects: 60
Study 17933159 — intervention group
Group type: EXPERIMENTAL
Intervention: Myolaxin ointment
Number of subjects: 60
Study 16244513 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint admission of children (21 mothers)
Number of subjects: 43
Study 16244513 — intervention group
Group type: COMPARATOR
Intervention: No joint admission of children (22 mothers)
Number of subjects: 43
Study 12148914 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention program to enhance knowledge and self-efficacy
Number of subjects: 0
Study 12148914 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 0
Study 11232606 — intervention group
Group type: EXPERIMENTAL
Intervention: Time from cardioversion to first episode recurrence
Number of subjects: 134
Study 11232606 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-over design
Number of subjects: 134
Study 9884845 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 58
Study 9884845 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 58
Study 7987906 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine mouthrinse
Number of subjects: 0
Study 7987906 — intervention group
Group type: COMPARATOR
Intervention: Phenolic mouthrinse
Number of subjects: 0
Study 2688037 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimipramine
Number of subjects: 0
Study 2688037 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 0
Study 1060356 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracervical block (PCB) with adrenaline
Number of subjects: 52
Study 1060356 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracervical block (PCB) without adrenaline
Number of subjects: 52
Study 1060356 — intervention group
Group type: COMPARATOR
Intervention: Epidural block
Number of subjects: 52
Study 7435798 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg orally once a week)
Number of subjects: 1125
Study 7435798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1125
Study 7435798 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline and Placebo
Number of subjects: 1125
Study 31707826 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 18924
Study 31707826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18924
Study 30280648 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-use group
Number of subjects: 1406
Study 30280648 — intervention group
Group type: COMPARATOR
Intervention: Broader-use group
Number of subjects: 1406
Study 27241671 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum with CPP-ACP (PI)
Number of subjects: 19
Study 27241671 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum without CPP-ACP (PII)
Number of subjects: 19
Study 27241671 — intervention group
Group type: COMPARATOR
Intervention: Control phase (salivary effect without stimulation, PIII)
Number of subjects: 19
Study 25313574 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fructo-oligosaccharide (FOS) supplementation (0, 1, 2 and 3%)
Number of subjects: 323
Study 25313574 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fructo-oligosaccharide (FOS) supplementation (2 and 3%)
Number of subjects: 323
Study 22500383 — intervention group
Group type: EXPERIMENTAL
Intervention: Guilin Watermelon Frost (GWF) local spray
Number of subjects: 160
Study 22500383 — intervention group
Group type: COMPARATOR
Intervention: bFGF-collagen sponge (Control)
Number of subjects: 160
Study 19967420 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC) 1,800 mg
Number of subjects: 30
Study 19967420 — intervention group
Group type: EXPERIMENTAL
Intervention: Epigallocatechin gallate (EGCG) 1,800 mg
Number of subjects: 30
Study 19967420 — intervention group
Group type: COMPARATOR
Intervention: Placebo (fiber - glucomannan) 1,000 mg
Number of subjects: 30
Study 18008241 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly IPTp (sulfadoxine-pyrimethamine)
Number of subjects: 456
Study 18008241 — intervention group
Group type: COMPARATOR
Intervention: Standard 2-dose IPTp (sulfadoxine-pyrimethamine)
Number of subjects: 456
Study 16247737 — intervention group
Group type: EXPERIMENTAL
Intervention: 700 mg glycine sublingually
Number of subjects: 40
Study 16247737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 12219187 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterol ester (PSE) treatment (2.8g/d = 1.68 phytosterols)
Number of subjects: 60
Study 12219187 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no treatment)
Number of subjects: 60
Study 12219187 — intervention group
Group type: COMPARATOR
Intervention: Margarine (20g/d)
Number of subjects: 60
Study 10526342 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual attention modulation
Number of subjects: 0
Study 10526342 — intervention group
Group type: EXPERIMENTAL
Intervention: Equivalent motion energy measurement
Number of subjects: 0
Study 8576675 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinacanthus nutans extract applied five times daily for 7-14 days
Number of subjects: 51
Study 8576675 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinacanthus nutans extract
Number of subjects: 51
Study 8576675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 1840336 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 0
Study 1840336 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium lactate
Number of subjects: 0
Study 1840336 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate combined with cinnarizine
Number of subjects: 0
Study 7100261 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine
Number of subjects: 0
Study 7100261 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0
Study 30932133 — intervention group
Group type: EXPERIMENTAL
Intervention: RJ group (BCAA-enriched nutritional supplements, 2500 mg BCAA and 20 IU vitamin D, twice a day until hospital discharge)
Number of subjects: 80
Study 30932133 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 80
Study 30932133 — intervention group
Group type: EXPERIMENTAL
Intervention: RJ group
Number of subjects: 80
Study 30932133 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 29781649 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy augmented by a relational focus (CBT‐R)
Number of subjects: 100
Study 29781649 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated exposure‐applied relaxation (GEAR)
Number of subjects: 100
Study 29781649 — intervention group
Group type: COMPARATOR
Intervention: Wait list (WL) control
Number of subjects: 100
Study 27817813 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol Easyhaler (320/9 μg)
Number of subjects: 72
Study 27817813 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol Easyhaler (1280/36 μg)
Number of subjects: 72
Study 27817813 — intervention group
Group type: COMPARATOR
Intervention: Symbicort Turbuhaler (320/9 μg)
Number of subjects: 72
Study 27817813 — intervention group
Group type: COMPARATOR
Intervention: Symbicort Turbuhaler (1280/36 μg)
Number of subjects: 72
Study 27817813 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol Easyhaler and Symbicort Turbuhaler
Number of subjects: 72
Study 24856796 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 46
Study 24856796 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 46
Study 22253903 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (IL-1 receptor antagonist)
Number of subjects: 26
Study 22253903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 20606660 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitor (PPI) treatment
Number of subjects: 0
Study 20606660 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal of PPI
Number of subjects: 0
Study 17389561 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation electrically heated cigarette smoking system (EHCSS)
Number of subjects: 100
Study 16310604 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical examination for signs of DVT using method 1 (DVT Risk Stratification System)
Number of subjects: 239
Study 16310604 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical examination for signs of DVT using method 2 (DVT Risk Score)
Number of subjects: 239
Study 12032522 — intervention group
Group type: EXPERIMENTAL
Intervention: DTO and phenobarbital
Number of subjects: 20
Study 12032522 — intervention group
Group type: COMPARATOR
Intervention: DTO alone
Number of subjects: 20
Study 10396200 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior transposition
Number of subjects: 20
Study 10396200 — intervention group
Group type: COMPARATOR
Intervention: Myectomy
Number of subjects: 20
Study 7745514 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic surfactant
Number of subjects: 419
Study 7745514 — intervention group
Group type: COMPARATOR
Intervention: Air placebo
Number of subjects: 419
Study 2248842 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lignocaine
Number of subjects: 8
Study 2248842 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride solution (control)
Number of subjects: 8
Study 760746 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propantheline bromide (15 mg)
Number of subjects: 6
Study 760746 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral propantheline bromide (15 mg)
Number of subjects: 6
Study 30827722 — intervention group
Group type: EXPERIMENTAL
Intervention: Arabinoxylan oligosaccharides (AXOS) 10.4 g/d
Number of subjects: 27
Study 30827722 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acids (PUFA) 3.6 g/d n-3 PUFA
Number of subjects: 27
Study 29873077 — intervention group
Group type: EXPERIMENTAL
Intervention: Total red meat intake (50 g/1,000 kcal increase)
Number of subjects: 407270
Study 29873077 — intervention group
Group type: EXPERIMENTAL
Intervention: Unprocessed red meat intake
Number of subjects: 407270
Study 29873077 — intervention group
Group type: EXPERIMENTAL
Intervention: White meat intake (50 g/1,000 kcal increase)
Number of subjects: 407270
Study 29873077 — intervention group
Group type: EXPERIMENTAL
Intervention: Heme iron (highest quintile)
Number of subjects: 407270
Study 29873077 — intervention group
Group type: EXPERIMENTAL
Intervention: HCAs (highest quintile)
Number of subjects: 407270
Study 29873077 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate/nitrite (highest quintile)
Number of subjects: 407270
Study 26496016 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine+Sertraline
Number of subjects: 0
Study 26496016 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine+Placebo
Number of subjects: 0
Study 25171998 — intervention group
Group type: EXPERIMENTAL
Intervention: HPPTUS-9
Number of subjects: 24
Study 25171998 — intervention group
Group type: EXPERIMENTAL
Intervention: HPPTUS-5
Number of subjects: 24
Study 25171998 — intervention group
Group type: COMPARATOR
Intervention: Conventional US
Number of subjects: 24
Study 22499288 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 9193
Study 22499288 — intervention group
Group type: COMPARATOR
Intervention: Atenolol-based treatment
Number of subjects: 9193
Study 22499288 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan and Atenolol-based treatment
Number of subjects: 9193
Study 20614049 — intervention group
Group type: COMPARATOR
Intervention: Atraumatic extraction (group A, n = 101 extraction sites)
Number of subjects: 125
Study 20614049 — intervention group
Group type: COMPARATOR
Intervention: Atraumatic extraction sealing the socket with autogenous soft tissue graft (group B, n = 39)
Number of subjects: 125
Study 20614049 — intervention group
Group type: COMPARATOR
Intervention: Atraumatic extraction with socket seal surgery and collagen matrix impregnated with gentamicin (group C, n = 33)
Number of subjects: 125
Study 18525300 — intervention group
Group type: EXPERIMENTAL
Intervention: Pd-103 implantation with 90 Gy
Number of subjects: 568
Study 18525300 — intervention group
Group type: EXPERIMENTAL
Intervention: Pd-103 implantation with 115 Gy
Number of subjects: 568
Study 18525300 — intervention group
Group type: EXPERIMENTAL
Intervention: 44 Gy preimplant supplemental beam radiation
Number of subjects: 568
Study 18525300 — intervention group
Group type: COMPARATOR
Intervention: 20 Gy preimplant supplemental beam radiation
Number of subjects: 568
Study 16044063 — intervention group
Group type: EXPERIMENTAL
Intervention: office-based vision therapy/orthoptics
Number of subjects: 46
Study 16044063 — intervention group
Group type: COMPARATOR
Intervention: office-based placebo vision therapy/orthoptics
Number of subjects: 46
Study 16044063 — intervention group
Group type: COMPARATOR
Intervention: home-based pencil pushups
Number of subjects: 46
Study 12014591 — intervention group
Group type: EXPERIMENTAL
Intervention: PEA‐BP
Number of subjects: 268
Study 12014591 — intervention group
Group type: COMPARATOR
Intervention: ADHD
Number of subjects: 268
Study 12014591 — intervention group
Group type: COMPARATOR
Intervention: CC
Number of subjects: 268
Study 9915532 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour NGT removal (study group)
Number of subjects: 175
Study 9915532 — intervention group
Group type: COMPARATOR
Intervention: Clinical signs of return of bowel function (control group)
Number of subjects: 175
Study 7751409 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (AMI) and Fluoxetine (FLU) combination
Number of subjects: 15
Study 7751409 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (AMI) alone
Number of subjects: 15
Study 2209270 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (31.5 Gy in 3.5 weeks)
Number of subjects: 0
Study 2209270 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative radiotherapy)
Number of subjects: 0
Study 6106110 — intervention group
Group type: EXPERIMENTAL
Intervention: Premedication with diazepam before endoscopy with a narrow instrument (9 mm)
Number of subjects: 0
Study 6106110 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy with a larger instrument (13 mm) after diazepam sedation
Number of subjects: 0
Study 6106110 — intervention group
Group type: COMPARATOR
Intervention: Upper gastrointestinal endoscopy without sedation using a small diameter instrument (9 mm)
Number of subjects: 0
Study 31152309 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa (NS) oil capsules (1350 mg/day)
Number of subjects: 0
Study 31152309 — intervention group
Group type: COMPARATOR
Intervention: Metformin tablets
Number of subjects: 0
Study 28826745 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of 0.5% ropivacaine for 96 hours
Number of subjects: 75
Study 28826745 — intervention group
Group type: COMPARATOR
Intervention: Sham infusion (normal saline) for 96 hours
Number of subjects: 75
Study 28826745 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no device)
Number of subjects: 75
Study 25351453 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (10 g 3 times a day)
Number of subjects: 40
Study 25351453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23988855 — intervention group
Group type: EXPERIMENTAL
Intervention: α-Lipoic acid (ALA) treatment for 2 days (600 mg orally three times a day before and after coronary catheterization, n = 100)
Number of subjects: 202
Study 23988855 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 102)
Number of subjects: 202
Study 21481742 — intervention group
Group type: EXPERIMENTAL
Intervention: Rufinamide (up to 45 mg/kg daily) as adjunctive therapy
Number of subjects: 918
Study 21481742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 918
Study 19686530 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 1208
Study 19686530 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended treatment with varenicline
Number of subjects: 1208
Study 19686530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1208
Study 16378696 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive hypoglycemia (RH) group
Number of subjects: 46
Study 16378696 — intervention group
Group type: COMPARATOR
Intervention: Non-reactive hypoglycemia (non-RH) group
Number of subjects: 46
Study 15304151 — intervention group
Group type: EXPERIMENTAL
Intervention: ABMK treatment (Agaricus blazei Murill Kyowa)
Number of subjects: 100
Study 15304151 — intervention group
Group type: COMPARATOR
Intervention: Nontreated placebo group
Number of subjects: 100
Study 11300443 — intervention group
Group type: EXPERIMENTAL
Intervention: RADIUS self-expanding stent
Number of subjects: 62
Study 11300443 — intervention group
Group type: COMPARATOR
Intervention: Palmaz-Schatz balloon-expandable stent
Number of subjects: 62
Study 9027671 — intervention group
Group type: EXPERIMENTAL
Intervention: Dirithromycin for 5 days
Number of subjects: 334
Study 9027671 — intervention group
Group type: COMPARATOR
Intervention: Amoxiclav for 7-10 days
Number of subjects: 334
Study 9027671 — intervention group
Group type: EXPERIMENTAL
Intervention: Dirithromycin
Number of subjects: 334
Study 9027671 — intervention group
Group type: COMPARATOR
Intervention: Amoxiclav
Number of subjects: 334
Study 8282361 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 10 mg given at 6 AM on awakening
Number of subjects: 6
Study 8282361 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 10 mg given at 8:30 AM after breakfast
Number of subjects: 6
Study 8282361 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 10 mg given at 6 PM after supper
Number of subjects: 6
Study 8282361 — intervention group
Group type: COMPARATOR
Intervention: Placebo during control period
Number of subjects: 6
Study 2662394 — intervention group
Group type: EXPERIMENTAL
Intervention: Holte Sleeping Technique
Number of subjects: 56
Study 2662394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 2662394 — intervention group
Group type: COMPARATOR
Intervention: No-treatment
Number of subjects: 56
Study 31339460 — intervention group
Group type: COMPARATOR
Intervention: Balance and motor control training (BMCT)
Number of subjects: 71
Study 31339460 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT)
Number of subjects: 71
Study 30462198 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation with an 8 mm‐tip catheter (CRYO)
Number of subjects: 158
Study 30462198 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 158
Study 26317176 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 237
Study 26317176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study 26317176 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Varenicline and Placebo
Number of subjects: 237
Study 23080326 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 119
Study 23080326 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation (RF)
Number of subjects: 119
Study 20188348 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttraumatic Avoidance Behaviour Questionnaire (PABQ)
Number of subjects: 437
Study 18682739 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week primaquine (PQ) regimen (0.75 mg/kg/week)
Number of subjects: 200
Study 18682739 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day primaquine (PQ) regimen (0.5 mg/kg/day)
Number of subjects: 200
Study 18682739 — intervention group
Group type: COMPARATOR
Intervention: Placebo (once weekly 8-week)
Number of subjects: 200
Study 16374224 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy screening (FS)
Number of subjects: 6961
Study 16374224 — intervention group
Group type: COMPARATOR
Intervention: Control group (not invited to screening)
Number of subjects: 6961
Study 14673492 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning through research papers
Number of subjects: 0
Study 14673492 — intervention group
Group type: COMPARATOR
Intervention: Textbook instruction
Number of subjects: 0
Study 10809915 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracutaneous injections of botulinum toxin (Botox(R)) 2 U/4 cm2
Number of subjects: 28
Study 9863158 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100 mg.d‐1)
Number of subjects: 0
Study 9863158 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (100 mg)
Number of subjects: 0
Study 1912368 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC+FT+Bestatin
Number of subjects: 96
Study 1912368 — intervention group
Group type: COMPARATOR
Intervention: MMC+FT
Number of subjects: 96
Study 6125636 — intervention group
Group type: EXPERIMENTAL
Intervention: No-added-sodium diet
Number of subjects: 90